AI Agent Library
Browse and manage your collection of AI agents
MOTION-OA 301
A Phase 3, randomized, double-blind, placebo-controlled study evaluating an investigational non-opioid therapy (NST-401) in adults with symptomatic osteoarthritis of the knee or hip using conversational AI, WOMAC assessment, and voice-based sentiment analysis (Hume AI).
WOMAC Hip - Knee Assessment Support Agent
When a user asks for help during an intervention in regard to their assessment, this agent takes over the conversation.
WOMAC Hip - Knee Assessment Agent
A Phase 3, randomized, double-blind, placebo-controlled study evaluating an investigational non-opioid therapy (NST-401) in adults with symptomatic osteoarthritis of the knee or hip using conversational AI, WOMAC assessment, and voice-based sentiment analysis (Hume AI).
CGM-Guided Diabetes Management in Type 2 Diabetes (CGMDM-T2D)
A multi-center, randomized controlled trial evaluating the efficacy of continuous glucose monitoring (CGM) in improving glycemic control and reducing hypoglycemic events in adults with Type 2 diabetes on intensive insulin therapy. This 52-week study will assess HbA1c reduction, time in range (70-180 mg/dL), hypoglycemia frequency, and patient-reported quality of life outcomes.
Study Kit Onboarding
This AI agent performs the task of onboarding a new trial participant, walking them through the process step by step.
Threshold Alert (English)
This agent is on the ready to respond to threshold alerts when sensor data exceeds an established range.
CGM PROs - (English)
This agent is available on demand for test subjects to report their experiences.
CGM Daily Check-in (English)
This agent checks in regularly to gather test subject feedback that is mapped to CGM data.
CGM Baseline Test (English)
This AI Agent's task is to gather baseline from a test subject during the first week of the trial. This allows customization of their threshold alerts.
CGM Device Error (English)
This AI Agent is responsible for connecting to test subjects to notify them that their device is not sending data.
MTX-402 for Treatment-Resistant Depression (TRIUMPH Study)
Phase III randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of MTX-402, a novel NMDA receptor modulator, in adults with treatment-resistant major depressive disorder. The study evaluates change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores over 12 weeks, with secondary endpoints including remission rates, quality of life, and functional disability measures.
No agents in this trial yet
Remote Cardiac Monitoring in Heart Failure Patients (HeartWatch-HF)
Prospective cohort study assessing the impact of AI-powered remote cardiac monitoring on hospital readmissions and mortality in patients with chronic heart failure (NYHA Class II-III). Study utilizes wearable ECG monitors, continuous weight tracking, and AI-driven alert systems to enable early intervention. Primary outcome: 90-day hospital readmission rates; Secondary outcomes include mortality, quality of life, healthcare costs, and patient satisfaction.
No agents in this trial yet